WO2026133248 - LIPOPROTEIN A LOWERING THERAPY
National phase entry is expected:
Publication Number
WO/2026/133248
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063174
International Filing Date
18.12.2025
Title **
[English]
LIPOPROTEIN A LOWERING THERAPY
[French]
THÉRAPIE D'ABAISSEMENT DE LA LIPOPROTÉINE A
Applicants **
NOVARTIS AG
Inventors
CAO, Hui
GEORGOUSIS, Vivian C.
LANDIE, Celine
WANG, Jing
Priority Data
63/736,727
20.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5770 | |
| EPO | Filing, Examination, Granting | 146206 | |
| Japan | Filing, Examination, Granting | 5146 | |
| South Korea | Filing, Examination, Granting | 10115 | |
| USA | Filing, Examination, Granting | 39940 |
Total:
207,177
Contact Us
Abstract[English]
The present disclosure relates to Lp(a) inhibitors such as pelacarsen for the treatment of subjects in need of Lp(a) lowering therapy, for example subjects having elevated Lp(a), and who is receiving or who is to receive PCSK9 inhibitor (e.g., inclisiran) therapy for elevated LDL-C.[French]
La présente divulgation concerne des inhibiteurs de Lp(a) tels que le pelacarsen pour le traitement de sujets ayant besoin d'une thérapie d'abaissement de Lp(a), par exemple des sujets ayant une Lp(a) élevée, et qui reçoivent ou qui doivent recevoir une thérapie par un inhibiteur de PCSK9 (par exemple, l'inclisiran) pour une LDL-C élevée.